Overview
HER2-positive gastric cancer is a subtype of gastric adenocarcinoma characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2). This molecular alteration significantly impacts tumor biology, leading to more aggressive clinical behavior and poorer outcomes compared to HER2-negative gastric cancers. It predominantly affects older adults, with a slight male predominance, and is recognized as a distinct entity due to its responsiveness to targeted therapies. Understanding and managing HER2-positive gastric cancer is crucial in day-to-day practice for optimizing patient outcomes through personalized treatment strategies 12.Pathophysiology
The pathophysiology of HER2-positive gastric cancer revolves around the amplification or overexpression of the HER2 gene, leading to hyperactivation of downstream signaling pathways crucial for cell proliferation, survival, and angiogenesis. This overexpression typically results from gene amplification rather than point mutations, driving uncontrolled cell growth and resistance to conventional chemotherapy. The aberrant signaling through pathways such as PI3K/AKT and RAS/MAPK contributes to tumor aggressiveness and metastatic potential. Additionally, the microenvironment is influenced by HER2 signaling, promoting immune evasion and tumor progression. Despite these mechanisms, targeted therapies aimed at inhibiting HER2 signaling have shown promise in improving survival rates 2.Epidemiology
HER2-positive gastric cancer constitutes approximately 10-20% of all gastric adenocarcinomas, with incidence varying geographically. Higher prevalence rates are noted in certain Asian populations compared to Western countries. The disease predominantly affects individuals over the age of 50, with a male-to-female ratio skewed slightly towards males. Risk factors include chronic Helicobacter pylori infection and environmental exposures, though the exact contribution of HER2 status to these risk factors remains an area of ongoing research. Trends suggest an increasing awareness and diagnostic capability leading to more accurate identification of HER2 status, potentially influencing treatment paradigms 2.Clinical Presentation
Patients with HER2-positive gastric cancer often present with nonspecific symptoms such as dyspepsia, weight loss, and anemia, which can overlap with HER2-negative cases. More specific red-flag features include rapid disease progression, early metastasis, particularly to the peritoneum and liver, and a higher likelihood of serosal invasion. Advanced stages may manifest with more pronounced systemic symptoms like cachexia and paraneoplastic syndromes. Early recognition of these features is critical for timely diagnosis and intervention 2.Diagnosis
The diagnostic approach for HER2-positive gastric cancer involves a combination of imaging, endoscopy with biopsy, and molecular testing. Specific criteria and tests include:(Evidence: Strong 2)
Management
First-Line Treatment
Second-Line Treatment
Refractory or Specialist Escalation
(Evidence: Moderate 2)
Complications
(Evidence: Moderate 2)
Prognosis & Follow-Up
The prognosis for HER2-positive gastric cancer is generally poorer compared to HER2-negative cases, though targeted therapies have improved survival rates. Prognostic indicators include stage at diagnosis, performance status, and response to initial therapy. Recommended follow-up includes:(Evidence: Moderate 2)
Special Populations
(Evidence: Moderate 2)
Key Recommendations
References
1 Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al.. First-Line Lorlatinib or Crizotinib in Advanced . The New England journal of medicine 2020. link 2 Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF et al.. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer chemotherapy and pharmacology 2013. link 3 Habs M, Eisenbrand G, Habs H, Schmähl D. No evidence of carcinogenicity of N-nitrosocimetidine in rats. Hepato-gastroenterology 1982. link